Загрузка...
Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report
PURPOSE: In National Wilms Tumor Study 5 (NWTS-5), tumor-specific combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p/16q) was associated with adverse outcomes in patients with favorable histology Wilms tumor. The AREN0533/AREN0532 studies assessed whether augmenting therapy improved ev...
Сохранить в:
| Опубликовано в: : | J Clin Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Clinical Oncology
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7001789/ https://ncbi.nlm.nih.gov/pubmed/31449468 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01972 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|